GRI Bio closes $8.0M public offering of common stock and Series F warrants

GRI Bio, Inc.

Offering of 10,666,667 shares (or equivalents) plus Series F warrants to buy same number at $0.75/share.
Gross proceeds $8.0M; H.C. Wainwright acted as exclusive placement agent.
Series F warrants exercisable immediately at $0.75, expire in five years; potential additional $8.0M if fully cash-exercised.
Proceeds to fund product development, working capital, and general corporate purposes.
Post-offering stockholders' equity exceeds $2.5 million, addressing Nasdaq continued listing requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.